Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 8/20 | 0.48 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7616155 | 1.00 | PRPS1 (0.48) | PRPS1HCAR1THRBCCNT1CDK9 | |
| SCHEMBL7616161 | 1.00 | PRPS1 (0.48) | PRPS1HCAR1THRBCCNT1CDK9 | |
| SCHEMBL8659894 | 0.83 | AHCY (0.52) | PRPS1THRBCCNT1CDK9KCNH2 | |
| SCHEMBL8659891 | 0.83 | AHCY (0.52) | PRPS1THRBCCNT1CDK9KCNH2 | |
| SCHEMBL15206412 | 0.78 | HCAR1 (0.51) | PRPS1HCAR1HSD17B10GAA | |
| SCHEMBL15206409 | 0.78 | HCAR1 (0.51) | PRPS1HCAR1HSD17B10GAA | |
| SCHEMBL15206411 | 0.78 | HCAR1 (0.51) | PRPS1HCAR1HSD17B10GAA | |
| SCHEMBL8586347 | 0.77 | THRB (0.41) | PRPS1THRBKCNH2 | |
| SCHEMBL8586343 | 0.77 | THRB (0.41) | PRPS1THRBKCNH2 | |
| SCHEMBL15205668 | 0.76 | HCAR1 (0.49) | PRPS1HCAR1HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455507-B1 | E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO WELLCOME INC. | 2002-07-18 | — | — | US | disclosed |
| EP-0994890-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998056761-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | ZC3HAV1, BRPF3, BRD3 | PRPS1 1137/4885HCAR1 3299/4885THRB 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.